Antinuclear antibodies and progression of quantitative interstitial lung changes: The Multi-Ethnic Study of Atherosclerosis (MESA)-Lung Study

IF 3.5 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Respiratory medicine Pub Date : 2025-01-23 DOI:10.1016/j.rmed.2025.107955

Kathryn Friedman Flack , Michael D. George , John S. Kim , Jesse Y. Hsu , Anna J. Podolanczuk , Eric A. Hoffman , Cheilonda Johnson , Claire F. McGroder , Benjamin M. Smith , Maryl Kreider , Steven M. Kawut , R. Graham Barr , Michaela R. Anderson , Elana J. Bernstein

{"title":"Antinuclear antibodies and progression of quantitative interstitial lung changes: The Multi-Ethnic Study of Atherosclerosis (MESA)-Lung Study","authors":"Kathryn Friedman Flack , Michael D. George , John S. Kim , Jesse Y. Hsu , Anna J. Podolanczuk , Eric A. Hoffman , Cheilonda Johnson , Claire F. McGroder , Benjamin M. Smith , Maryl Kreider , Steven M. Kawut , R. Graham Barr , Michaela R. Anderson , Elana J. Bernstein","doi":"10.1016/j.rmed.2025.107955","DOIUrl":null,"url":null,"abstract":"<div><div>Antinuclear antibodies (ANA) are often found in ILD; whether ANA is associated with radiographic progression of quantitive interstitial lung changes is unknown. We performed longitudinal analyses of adults in the Multi-Ethnic Study of Atherosclerosis using linear mixed effects models with random intercept and slope to evaluate whether baseline ANA was associated with change in the amount of lung with high attenuation areas on CT (HAAs, percentage of imaged lung with −600 to −250 HU). In 6,638 subjects with 17,293 CT scans over 18 years, 741 (11 %) were ANA positive. ANA was not associated with HAA progression with ANA as a dichotomous variable (0.13 % less progression per year for ANA positive vs negative, 95%CI -0.33 %–0.07 %, p = 0.19) or as a continuous variable (0.004 % less progression per year per 10 % increase in ANA, 95%CI -0.01 %–0.005 %, p = 0.37). ANA was not associated with progression of HAA in community dwelling adults.</div></div>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"238 ","pages":"Article 107955"},"PeriodicalIF":3.5000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0954611125000174","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Antinuclear antibodies (ANA) are often found in ILD; whether ANA is associated with radiographic progression of quantitive interstitial lung changes is unknown. We performed longitudinal analyses of adults in the Multi-Ethnic Study of Atherosclerosis using linear mixed effects models with random intercept and slope to evaluate whether baseline ANA was associated with change in the amount of lung with high attenuation areas on CT (HAAs, percentage of imaged lung with −600 to −250 HU). In 6,638 subjects with 17,293 CT scans over 18 years, 741 (11 %) were ANA positive. ANA was not associated with HAA progression with ANA as a dichotomous variable (0.13 % less progression per year for ANA positive vs negative, 95%CI -0.33 %–0.07 %, p = 0.19) or as a continuous variable (0.004 % less progression per year per 10 % increase in ANA, 95%CI -0.01 %–0.005 %, p = 0.37). ANA was not associated with progression of HAA in community dwelling adults.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Respiratory medicine 医学-呼吸系统

CiteScore

7.50

自引率

0.00%

发文量

199

审稿时长

38 days

期刊介绍： Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants. Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.